Crinetics Pharmaceuticals In (CRNX) 13F Positioning & Ownership Changes (Q2 2026)

CRNX ranks #2341 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

269 institutions disclose a position in CRNX, but none treat it as a major bet — even First Light Asset Management, LLC, its most concentrated holder, allocates just 3.1% of its own portfolio to it.

T. Rowe Price has added to its CRNX position for two straight quarters, increasing it by $72.5M to reach $75.2M today.

Wellington Management Group LLP has trimmed its CRNX position for two straight quarters, cutting it by $107.3M while still holding $266.8M.

CRNX is down 0% today, but institutions show net buying of $439.3M this quarter — a divergence between today's price move and the underlying institutional flow.

CRNX reported a net loss of $501.6M over the trailing twelve months.

• Not yet profitable — net loss of $501.6M over the trailing twelve months
• Revenue grew 2928.4% year over year
• Net income declined year over year, from -$369.8M to -$501.6M
• Operating cash flow was negative, using $377.9M in cash
• Current ratio of 12.32x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.14x equity — within a conventional range